Alto Neuroscience Receives FDA Fast Track Designation for ALTO-101 for the Treatment of Cognitive Impairment Associated with Schizophrenia

Core Viewpoint - Alto Neuroscience, Inc. has received Fast Track designation from the U.S. FDA for its drug ALTO-101, aimed at treating cognitive impairment associated with schizophrenia, a condition currently lacking approved treatments [1] Company Summary - Alto Neuroscience is a clinical-stage biopharmaceutical company focused on developing precision medicines for neuropsychiatric disorders [1] Industry Summary - Cognitive impairment associated with schizophrenia (CIAS) is identified as a core feature of schizophrenia, highlighting a significant unmet medical need in the treatment landscape [1]